Treatment guidelines for type 2 diabetes (T2D) recommend avoidance of hypoglycemia and less stringent glycemic control in older patients. We examined the relation of glycemic control to glucoselowering medications use in a cohort of patients aged>80 years with a diagnosis of T2D and a hospital admission in the Capital Region of Denmark in 2012-2016. We extracted data on medication use, diagnoses, and biochemistry from the hospitals' records. We identified 5,172 T2D patients with high degree of co-morbidity and where 17% had an HbA 1c in the range recommended for frail, comorbid, older patients with type 2 diabetes (58-75 mmol/mol (7.5-9%)). Half of the patients (n = 2,575) had an HbA 1c <48 mmol/mol (<6.5%), and a majority of these (36% of all patients) did not meet the diagnostic criteria for T2D. Of patients treated with one or more glucose-lowering medications (n = 1,758), 20% had HbA 1c -values <42 mmol/mol (<6%), and 1% had critically low Hba 1c values <30 mmol/mol (<4.9%), In conclusion, among these hospitalized T2D patients, few had an HbA 1c within the generally recommended glycemic targets. One third of patients did not meet the diagnostic criteria for T2D, and of the patients who were treated with glucose-lowering medications, one-fifth had HbA 1c -values suggesting overtreatment.
Glucose-lowering medications. Close to one third of patients (34%, n = 1,758) were treated with at least one glucose-lowering medication at discharge (Table 3) ; 41% (n = 2,100) were administered at least one glucose-lowering medication, including sliding scale bolus insulin, during the index hospital admission (data not shown). Among the patients treated with glucose-lowering medication at discharge, one fourth (25%, n = 448) were treated with two or more glucose-lowering medications ( Table 3 ). The most commonly used glucose-lowering medications were metformin (50%), basal insulin (32%), bolus insulin (10%), sulphonylureas (14%) and dipeptidyl peptidase-4 inhibitors (14%) ( Table 4 ).
Glucose-lowering medications in relation to glycemic control.
Of those treated with a glucose-lowering medication at discharge (n = 1,758), close to half 48%, n = 844) had an HbA 1c within the interval recommended for elderly without significant comorbidity (43-57 mmol/mol (6.0-7.5%)). One third had higher HbA1c-values, 21% (n = 374) had a Hba1c between 58-74 mmol/mol (7.5-9) , and 10% (n = 182) had Hba1c >75 mmol/mol (9%); while the remaining 20% (n = 343) had near-normalized Hba1c (<42 mmol/mol (6%)) while continuing glucose-lowering medication at discharge. Of the patients with near-normalization of Hba1c values, 15% (n = 52) took two or more glucose-lowering medications ( Table 3 , Fig. 1 ) most frequently metformin, insulin and sulphonylureas (Table 4 ). One percent (n = 15) of the patients treated with an glucose-lowering medication at discharge had very low Hba 1c -values <30 mmol/mol (<4.9%) ( Table 3 , Fig. 1 ).
For those patients who did not receive a glucose-lowering medication at discharge (n = 3,414), 55% (n = 1,865) had HbA 1c -values that did not justify a diagnosis of type 2 diabetes (i.e. HbA 1c <48 mmol/mol (<6,5%)) ( Table 3 , Fig. 1 ). At the other end of the spectrum, 7% (n = 223) had Hba1c levels for which glucose-lowering medications are generally recommended (i.e.>75 mmol/mol (9%)).
Discussion
Based on hospital electronic health records covering the entire population of the Capital Region of Denmark (1.8 million inhabitants) from 2012 to 2016, we investigated the demographics and the degree of glycemic control in relation to glucose-lowering medications in patients with type 2 diabetes aged 80 years or more. Our main findings were (1) almost half of the patients had an HbA 1c <48 mmol/mol (<6,5%), and of these 72% (n = 1865, 36% of all patients) were not treated with a glucose-lowering medication and thus did not fulfil the diagnostic criteria of type 2 diabetes; (2) of the patients treated with one or more glucose-lowering medications (often including insulin and/or sulphonylureas), 20% had HbA 1c -values below 42 mmol/mol (6%) and 1% had critically low HbA 1c values <30 mmol/mol (<4.9%), indicating overtreatment. Conversely, 8% of all patients had Hba1c values >75 mmol/mol (>9%), indicating possible undertreatment.
A surprising finding was that based on HbA 1c -value, 36% (n = 1,865) of all the admitted patients did meet the criteria for their diagnosis of type 2 diabetes. The diagnoses were all registered by a physician authorized in Denmark and could have been registered many years prior to the index admission. Thus, one potential explanation for our finding could be that type 2 diabetes is not a chronic disease but rather a condition that may in some cases remit with old age -a notion that has been proposed before 32, 33 . Hence, Abdelhafiz et al. proposed that frailty among older people with type 2 diabetes might lead to the remission of type 2 diabetes with the suggested mechanisms being weight loss accompanied by reduced amounts of visceral fat and thereby improved insulin sensitivity 32 . Such a mechanism bears resemblance to that described for patients having bariatric surgery and/or substantial weight loss and afterwards experience remission of their type 2 diabetes 34, 35 . www.nature.com/scientificreports www.nature.com/scientificreports/ We report that only 17% of included patients had an HbA 1c between 58-75 mmol/mol (7.5-9%), the interval generally recommended for elderly with significant comorbidities and limited life expectancy. That our patients were indeed highly comorbid is evidenced by the Charlson comorbidity score, where 94% scored 2 or more 36 . Of those with an HbA 1c <42 mmol/mol (<6.0%), 25% were treated with one or more glucose-lowering medications. These findings are in line with findings from other studies that have raised concerns about the potential overtreatment of older people with type 2 diabetes 12,23,24,37-39 . Among these is a large register-based study by Tseng et al. including 652,738 patients from the Veteran Health Administration. They reported that approximately 50% of patients aged 75 years or older, who were treated with insulin and/or sulphonylureas, had an HbA 1c <53 mmol/mol (<7%) 12 . Similarly, results from The Fremantle Diabetes Cohort Study, which included 367 patients over the age of 75 with type 2 diabetes showed that approximately three of five (61%) of the patients had an HbA 1c <53 mmol/mol (<7%) 37 . As treatment needs to be individualized according to a patient's preferences and resources as well as life expectancy it is of interest that in our cohort dementia was registered as a diagnosis for 16% and non-skin malignancy for 19% of the included patients. Studies of frail patients with type 2 diabetes and limited life expectancy, such as nursing home residents, have suggested that particularly elderly with dementia are overtreated with glucose-lowering medications. Thus, in a nursing home population, 46-74% of the patients had an HbA 1c <53 mmol/mol (<7%) 24, 39, 40 . Although the distributions of Hba 1c -values in the mentioned nursing home studies were similar to ours, cognitive and functional impairment may be more frequent in the nursing home setting. One percent (n = 70) of our population had hypoglycemia as the primary cause of admission. However, this is likely an underestimate of the number of patients at high risk of hypoglycemia. In older people, hypoglycemia can go undiscovered and be difficult to recognize due to unspecific symptoms 11 . Thus, the substantial proportion of patients, who in the context of near-normal Hba1c (i.e. below 42 mmol/mol (6%)) continued treatment with a sulphonylurea (n = 70) or insulin (n = 82) could be considered at high risk of hypoglycemic events 11, 16 . Thus, our study adds to the evidence suggesting that the recommendations favoring looser glycemic control in elderly, comorbid people similar to our population has not been fully adopted into clinical practice.
Our study has important strengths such as the large sample size, the high data quality from rather accurate national registers with the possibility of linking biochemical data with health record data and drug use. Nonetheless, this register-based study also has some limitations. In our study, only 34% of elderly patients with a diagnosis of type 2 diabetes were treated with glucose-lowering medications. Other studies on glycemic control in older people, including the mentioned studies of nursing home residents and larger cohort studies report a much higher proportion of patients treated with glucose-lowering medication. Thus, between 85-100% of the patients received glucose-lowering medication in other cohort studies of a general population with type 2 diabetes 12, 23, 37 , and up to 86% were pharmacologically treated in studies investigating glycemic control in nursing home residents 24, 39, 40 . Our lower treatment prevalence is most likely due to the fact that many patients in our cohort did not meet the criteria for type 2 diabetes at the time of study. Since our study was based on a cohort identified by a hospital admission, and data analyses were limited to the time around hospital admission, we did not have information on the duration of diabetes or the glycemic control and use of antidiabetic medication over time. Access to this information could have strengthened our interpretation particularly the reason for the high proportion of patients not fulfilling the diagnostic criteria for type 2 diabetes. There is some indication that our cohort does not fully reflect the population in the capital region of Denmark. Thus, in our cohort, 54% were female, while the concurrent female proportion in the general population was 65%. The reason for such relative underrepresentation of females in our cohort is unclear. Another issue is that 56% had a hemoglobin below reference level, which theoretically could lead to an underestimation of the HbA 1c -values. However, as proposed by samples from another Danish population, mild to moderate anemia does not seem have significant impact on the interpretation of HbA 1c -values 41 . www.nature.com/scientificreports www.nature.com/scientificreports/ In this hospital-based cohort consisting of more than 5000 patients, few patients ≥80 years with type 2 diabetes had an HbA 1c within the limits generally recommended for this population. Many patients were not treated with glucose-lowering medications and had HbA 1c -values that could not justify a diagnosis of type 2 diabetes. Of Table 4 . Antidiabetic medication at the time of hospital discharge in relation to HbA 1c -values (obtained ±90 days before hospital admission) for very old patients with type 2 diabetes. Values are displayed in absolute numbers. HbA 1c -values are divided into categories and displayed in mmol/mol. Patients count more than once if administered more than one kind of antidiabetic. DPP-4i: dipeptidylpeptidase-4 inhibitor, SGLT-2i: sodiumglucose cotransporter-2 inhibitor, SU: sulfonylurea, GLP-1RA: Glucagon-like peptide-1 receptor agonist.
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